SCHEMBL22895585

SCHEMBL22895585

CC(C)(C)OC(=O)N1CC[C@@H](Nc2ncc(Cl)c(C(F)(F)F)n2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK12 Q9NYV4 7/20 0.49
▸ IDH1 O75874 2/20 0.49
▸ USP30 Q70CQ3 4/20 0.48
▸ MAPK3 P27361 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ CCNK O75909 6/20 0.45
▸ IDH2 P48735 1/20 0.44
▸ CDK13 Q14004 1/20 0.43
▸ JUN P05412 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ MAPK8 P45983 1/20 0.43
▸ MAPK9 P45984 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23292416 1.00 CDK12 (0.49) CDK12IDH1USP30MAPK3HDAC4
SCHEMBL28541041 1.00 CDK12 (0.49) CDK12IDH1USP30MAPK3HDAC4
SCHEMBL22895533 0.88 USP30 (0.52) CDK12IDH1USP30CCNKCDK13
SCHEMBL23292274 0.88 USP30 (0.52) CDK12IDH1USP30CCNKCDK13
SCHEMBL28552023 0.88 USP30 (0.52) CDK12IDH1USP30CCNKCDK13
SCHEMBL28544916 0.87 CDK12 (0.56) CDK12IDH1USP30CCNKCDK13
SCHEMBL23292333 0.87 CDK12 (0.56) CDK12IDH1USP30CCNKCDK13
SCHEMBL22895770 0.87 CDK12 (0.56) CDK12IDH1USP30CCNKCDK13
SCHEMBL23292227 0.87 CDK12 (0.65) CDK12IDH1USP30MAPK3HDAC4
SCHEMBL22895468 0.87 CDK12 (0.65) CDK12IDH1USP30MAPK3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358958-B2 — — 2022-06-14 — — US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 — — US disclosed
CN-112638373-A Cyclin-dependent kinase inhibitors 金耐特生物制药公司 2021-04-09 — — CN disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358958-B2 — CDK2, CDK1, CDK6 CDK12 19/4885IDH1 581/4885USP30 1508/4885
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 CDK12 22/4885IDH1 781/4885USP30 1863/4885
US-10894788-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 CDK12 22/4885IDH1 781/4885USP30 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback